share_log

Bruker Corp | 8-K: Bruker Reports Third Quarter 2024 Financial Results

Bruker Corp | 8-K: Bruker Reports Third Quarter 2024 Financial Results

布鲁克 | 8-K:布鲁克公布2024年第三季度财务业绩
美股SEC公告 ·  2024/11/05 07:01

Moomoo AI 已提取核心信息

Bruker reported Q3 2024 revenues of $864.4M, up 16.4% YoY, with organic revenue growth of 3.1% and CER revenue growth of 15.7%. BSI segment organic revenue increased 3.8% YoY. Q3 GAAP operating income was $68.1M, while non-GAAP operating income reached $129.1M with a 14.9% margin. GAAP diluted EPS was $0.27 and non-GAAP diluted EPS was $0.60.The company updated its FY2024 guidance, now expecting revenues of $3.34-3.37B, implying organic revenue growth of 3-4% and CER revenue growth of approximately 13% YoY. Non-GAAP EPS guidance was lowered to $2.36-2.41, reflecting delays in biopharma and China market recovery.Management noted gradual improvement in orders for differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions, with BSI organic bookings growing in upper mid-single digits in Q3. The company remains confident in driving above-market organic revenue growth with significant margin expansion in 2025.
Bruker reported Q3 2024 revenues of $864.4M, up 16.4% YoY, with organic revenue growth of 3.1% and CER revenue growth of 15.7%. BSI segment organic revenue increased 3.8% YoY. Q3 GAAP operating income was $68.1M, while non-GAAP operating income reached $129.1M with a 14.9% margin. GAAP diluted EPS was $0.27 and non-GAAP diluted EPS was $0.60.The company updated its FY2024 guidance, now expecting revenues of $3.34-3.37B, implying organic revenue growth of 3-4% and CER revenue growth of approximately 13% YoY. Non-GAAP EPS guidance was lowered to $2.36-2.41, reflecting delays in biopharma and China market recovery.Management noted gradual improvement in orders for differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions, with BSI organic bookings growing in upper mid-single digits in Q3. The company remains confident in driving above-market organic revenue growth with significant margin expansion in 2025.
布鲁克报告2024年第三季度营业收入为86440万美元,同比增长16.4%,有机营业收入增长3.1%,按固定汇率计算营业收入增长15.7%。BSI部门的有机营业收入同比增长3.8%。第三季度GAAP运营收入为6810万美元,而非GAAP运营收入达到12910万美元,利润率为14.9%。GAAP摊薄后每股收益为0.27美元,非GAAP摊薄后每股收益为0.60美元。公司更新了2024财年的指导,预计营业收入为334-337亿美元,意味着有机营业收入增长3-4%,按固定汇率计算营业收入同比增长约13%。非GAAP每股收益指导下调至2.36-2.41美元,反映了生物制药和中国市场复苏的延迟。管理层指出,针对差异化后基因组学、多组学、清洁技术、半导体和诊断解决方案的订单逐渐改善,BSI的有机订单在第三季度增长了中上个位数。公司对在2025年实现超出市场的有机营业收入增长并显著扩大利润率充满信心。
布鲁克报告2024年第三季度营业收入为86440万美元,同比增长16.4%,有机营业收入增长3.1%,按固定汇率计算营业收入增长15.7%。BSI部门的有机营业收入同比增长3.8%。第三季度GAAP运营收入为6810万美元,而非GAAP运营收入达到12910万美元,利润率为14.9%。GAAP摊薄后每股收益为0.27美元,非GAAP摊薄后每股收益为0.60美元。公司更新了2024财年的指导,预计营业收入为334-337亿美元,意味着有机营业收入增长3-4%,按固定汇率计算营业收入同比增长约13%。非GAAP每股收益指导下调至2.36-2.41美元,反映了生物制药和中国市场复苏的延迟。管理层指出,针对差异化后基因组学、多组学、清洁技术、半导体和诊断解决方案的订单逐渐改善,BSI的有机订单在第三季度增长了中上个位数。公司对在2025年实现超出市场的有机营业收入增长并显著扩大利润率充满信心。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息